Evidence map›Paper›PMID 40676267›Full record

ArticleEMBO molecular medicine2025

LIMA1-alpha staining predicts curative intent surgery response in HPV negative head and neck cancer.

Xi Qiao, Johannes Routila, Mari Tienhaara, Heikki Irjala, Priyadharshini Parimelazhagan Santhi, Teemu Huusko, Linda Nissi, Ilkka Paatero, Noora Lehtinen, Juha Rantala and 12 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in EMBO molecular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Xi Qiao *Turku Bioscience Centre, University of Turku and Åbo Akademi University, Tykistökatu 6, Turku, 20520, Finland.ORCID http://orcid.org/0000-0002-9795-6644
Johannes Routila *Department for Otorhinolaryngology, Head and Neck Surgery, University of Turku and Turku University Hospital, Kiinamyllynkatu 4-8, Turku, 20521, Finland.ORCID http://orcid.org/0000-0001-5385-7065
Mari TienhaaraInstitute of Biomedicine, and MediCity Research Laboratories, University of Turku, Turku, 20520, Finland.ORCID http://orcid.org/0009-0001-9198-082X
Heikki IrjalaDepartment for Otorhinolaryngology, Head and Neck Surgery, University of Turku and Turku University Hospital, Kiinamyllynkatu 4-8, Turku, 20521, Finland.ORCID http://orcid.org/0000-0003-3054-4677
Priyadharshini Parimelazhagan SanthiTurku Bioscience Centre, University of Turku and Åbo Akademi University, Tykistökatu 6, Turku, 20520, Finland.
Teemu HuuskoDepartment for Otorhinolaryngology, Head and Neck Surgery, University of Turku and Turku University Hospital, Kiinamyllynkatu 4-8, Turku, 20521, Finland.ORCID http://orcid.org/0009-0003-8790-9355
Linda NissiDepartment for Otorhinolaryngology, Head and Neck Surgery, University of Turku and Turku University Hospital, Kiinamyllynkatu 4-8, Turku, 20521, Finland.
Ilkka PaateroTurku Bioscience Centre, University of Turku and Åbo Akademi University, Tykistökatu 6, Turku, 20520, Finland.ORCID http://orcid.org/0000-0001-5926-2396
Noora LehtinenMisvik Biology Ltd, Karjakatu 35 B, Turku, 20520, Finland.
Juha RantalaMisvik Biology Ltd, Karjakatu 35 B, Turku, 20520, Finland.ORCID http://orcid.org/0000-0002-4999-5585
Toni ViljanenDepartment for Otorhinolaryngology, Head and Neck Surgery, University of Turku and Turku University Hospital, Kiinamyllynkatu 4-8, Turku, 20521, Finland.
Ilmo LeivoDepartment of Pathology, Turku University Hospital, Kiinamyllynkatu 4-8, Turku, 20521, Finland.
Petri KoivunenDepartment of Otorhinolaryngology, Head and Neck Surgery, University of Oulu and Oulu University Hospital, Oulu, Finland.ORCID http://orcid.org/0000-0003-4907-3705
Anna Jouppila-MättöDepartment of Otorhinolaryngology, Head and Neck Surgery, Kuopio University Hospital, Kuopio, Finland.
Rami TauluDepartment of Otorhinolaryngology, Head and Neck Surgery, Tampere University Hospital and University of Tampere, Tampere, Finland.
Leif BäckDepartment of Otorhinolaryngology, Head and Neck Surgery, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
Tommy WilkmanDepartment of Oral and Maxillofacial Diseases, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.ORCID http://orcid.org/0000-0001-5135-478X
Eeva HaapioDepartment for Otorhinolaryngology, Head and Neck Surgery, University of Turku and Turku University Hospital, Kiinamyllynkatu 4-8, Turku, 20521, Finland.ORCID http://orcid.org/0000-0002-3349-6829
Ilpo KinnunenDepartment for Otorhinolaryngology, Head and Neck Surgery, University of Turku and Turku University Hospital, Kiinamyllynkatu 4-8, Turku, 20521, Finland.
Kari KurppaInstitute of Biomedicine, and MediCity Research Laboratories, University of Turku, Turku, 20520, Finland.ORCID http://orcid.org/0000-0001-8286-2429
Jukka Westermarck *Turku Bioscience Centre, University of Turku and Åbo Akademi University, Tykistökatu 6, Turku, 20520, Finland. jukwes@utu.fi.ORCID http://orcid.org/0000-0001-7478-3018
Sami Ventelä *Turku Bioscience Centre, University of Turku and Åbo Akademi University, Tykistökatu 6, Turku, 20520, Finland. satuve@utu.fi.ORCID http://orcid.org/0000-0001-6672-6662

Funding

Academy of Finland 354599Business Finland 1278/31/2021Research Council of Finland's Flagship InFlames 337530Research Council of Finland's Flagship InFlames 357910
6 · The paper itself

Abstract

In many solid cancer types, surgery alone could be a sufficient first therapy option for a significant number of cancer patients. However, there are currently no diagnostic solutions to identify patients who could be stratified to surgery alone. To identify a biomarker predicting cancer surgery response, candidate biomarkers were studied in a non-metastatic head and neck squamous cell carcinoma (nmHNSCC) cohort well representative of the HPV-negative patient population. LIMA1 immunohistochemistry (IHC) with specificity-validated antibodies outperformed all other biomarkers in multivariable survival analyses of patients with nmHNSCC (n = 128, HR 2.10, P = 0.006). The prognostic effect was selective to LIMA1-alpha isoform IHC detection in patients who had received surgical therapy (n = 184, HR 2.39, P > 0.001). Strikingly, our real-world validation results, using two prospectively collected cohorts (n = 15 and n = 86), demonstrate that none of the LIMA1 negative patients died of HNSCC during the follow-up. Collectively, we report here the discovery of a diagnostic LIMA1-alpha IHC assay for HPV-negative HNSCC patient stratification to surgery-only therapy. Application of LIMA1 detection in routine nmHNSCC diagnostics would revolutionize the clinical management of HNSCC patients.

Indexed as

Biomarkers, TumorCarcinoma, Squamous CellHead and Neck NeoplasmsIntracellular Signaling Peptides and ProteinsAdultAgedCohort StudiesFemaleHumansImmunohistochemistryMaleMiddle AgedPrognosisSquamous Cell Carcinoma of Head and NeckSurvival AnalysisTreatment OutcomeBiomarkers, TumorIntracellular Signaling Peptides and ProteinsDisease-Specific SurvivalEPLINPopulation-validated Tissue MicroarrayPV-TMA

Identifiers

PMID40676267
PMCPMC12340046

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.